| 1.1 0 (0%) | 04-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.28 | 1-year : | 1.5 |
| Resists | First : | 1.1 | Second : | 1.28 |
| Pivot price | 1.08  |
|||
| Supports | First : | 1.07 | Second : | 1.05 |
| MAs | MA(5) : | 1.09 | MA(20) : | 1.08 |
| MA(100) : | 0.57 |
MA(250) : | 0.65 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 91.6 |
D(3) : | 83.3 |
| RSI | RSI(14): 74.1 | |||
| 52-week | High : | 1.27 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SCTL ] has closed below upper band by 19.4%. Bollinger Bands are 81.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 1.08 - 1.09 | 1.09 - 1.1 |
| Close: | 1.09 - 1.1 | 1.1 - 1.11 |
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Mon, 08 Apr 2024
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc. - Business Wire
Fri, 22 Mar 2024
Societal CDMO: Q4 Earnings Snapshot - Quartz
Wed, 13 Mar 2024
SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Thu, 29 Feb 2024
Why Is Biotech/Pharma Contract Service Provider Societal CDMO Stock Trading Higher On Thursday? - Markets Insider
Thu, 29 Feb 2024
Why Is Societal CDMO (SCTL) Stock Up 133% Today? - InvestorPlace
Wed, 28 Feb 2024
Societal CDMO's Merger and Tender Offer by CoreRx - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 106 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 45.3 (%) |
| Held by Institutions | 57.5 (%) |
| Shares Short | 271 (K) |
| Shares Short P.Month | 186 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | -14.1 % |
| Operating Margin | 2.7 % |
| Return on Assets (ttm) | -1.5 % |
| Return on Equity (ttm) | -22.4 % |
| Qtrly Rev. Growth | 14.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.89 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -7.86 |
| PEG Ratio | -0.9 |
| Price to Book value | 1.96 |
| Price to Sales | 1.22 |
| Price to Cash Flow | -116.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|